Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. Director Declaration

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Director Declaration

28 Oct 2025 07:05

RNS Number : 9938E
AstraZeneca PLC
28 October 2025
 

 

 

28 October 2025

 

Director Declaration

 

AstraZeneca PLC (the Company) today announced that Euan Ashley, Non-Executive Director of the Company, has been appointed a director of DexCom, Inc. with effect from 24 October 2025.

 

This announcement is made pursuant to Listing Rule 6.4.9 (2).

 

 

AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

 

Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Matthew BowdenCompany Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNQDLFLEBLZFBZ
161718192021222324
Date   Source Headline
11th Sep 20177:00 amRNSIMFINZI superior PFS in Stage III lung cancer
7th Sep 201712:39 pmRNSCelgene and AZ update on Fusion trial programme
7th Sep 20177:00 amRNSAZ Duaklir improves lung function in COPD patients
7th Sep 20177:00 amRNSAZ tezepelumab cuts exacerbations in severe asthma
5th Sep 20177:00 amRNSDirectorate Change
1st Sep 20173:00 pmRNSTotal Voting Rights
29th Aug 20177:00 amRNSFaslodex gets US FDA OK for expanded use in breast
18th Aug 20177:00 amRNSLynparza gets broad FDA approval in ovarian cancer
16th Aug 20177:00 amRNSDirectorate Change
14th Aug 20174:30 pmRNSHolding(s) in Company
10th Aug 20171:30 pmRNSPublication of a Prospectus
2nd Aug 20177:00 amRNSAZ acalabrutinib submission accepted by US FDA
1st Aug 20173:00 pmRNSTotal Voting Rights
1st Aug 20177:00 amRNSBTD for AZ's acalabrutinib in mantle cell lymphoma
31st Jul 20177:00 amRNSImfinzi granted BTD by US FDA for Stage III nsclc
28th Jul 201711:00 amRNSDirector/PDMR Shareholding
27th Jul 20177:15 amRNSTagrisso significantly improves FLAURA
27th Jul 20177:11 amRNSAZ reports initial results from MYSTIC lung trial
27th Jul 20177:06 amRNSAZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEAL
27th Jul 20177:00 amRNSAstraZeneca PLC - H1 2017 Results
26th Jul 20174:46 pmRNSFaslodex receives EU approval for 1L breast cancer
21st Jul 20173:45 pmRNSHolding(s) in Company
3rd Jul 20172:59 pmRNSTotal Voting Rights
3rd Jul 20177:00 amRNSAZ COMPLETES SELOKEN AGREEMENT WITH RECORDATI
3rd Jul 20177:00 amRNSAZ COMPLETES ZOMIG DIVESTMENT WITH GRÜNENTHAL
23rd Jun 201712:46 pmRNSFaslodex CHMP positive opinion in 1L breast cancer
7th Jun 20177:13 amRNSAZ agreement with Grünenthal for rights to Zomig
6th Jun 20177:00 amRNSASTRAZENECA PRICES A $2BN BOND ISSUE
5th Jun 20177:00 amRNSLYNPARZA: SIGNIFICANT PFS IN BRCAm BREAST CANCER
1st Jun 20173:00 pmRNSBlock listing Interim Review
1st Jun 20173:00 pmRNSTotal Voting Rights
31st May 20177:00 amRNSDirectorate Change
24th May 20173:00 pmRNSDirector/PDMR Shareholding
23rd May 20177:00 amRNSBydureon EXSCEL trial meets T2D safety objective
22nd May 20177:00 amRNSAZ AGREEMENT WITH RECORDATI FOR SELOKEN IN EUROPE
16th May 20173:00 pmRNSDirector/PDMR Shareholding
12th May 20177:00 amRNSIMFINZI SIGNIFICANT PFS - UNRESECTABLE LUNG CANCER
10th May 20177:00 amRNSAZ updates on tralokinumab trial in severe asthma
2nd May 20172:00 pmRNSTotal Voting Rights
2nd May 20177:00 amRNSDURVALUMAB RECEIVES US FDA ACCELERATED APPROVAL
27th Apr 20175:30 pmRNSResult of AGM
27th Apr 20177:00 amRNSAstraZeneca: Q1 2017 Results
25th Apr 20171:30 pmRNSTAGRISSO RECEIVES FULL APPROVAL IN THE EU
12th Apr 20175:34 pmRNSNotification of Major Interest in Shares
3rd Apr 20173:00 pmRNSTotal Voting Rights
31st Mar 20177:01 amRNSTagrisso (osimertinib) receives FDA full approval
31st Mar 20177:00 amRNSAZ COMPLETES AGREEMENT WITH TERSERA THERAPEUTICS
28th Mar 20174:00 pmRNSDirector/PDMR Shareholding
27th Mar 20173:00 pmRNSDirector/PDMR Shareholding
17th Mar 20177:00 amRNSUS FDA issues CRL for ZS-9 in hyperkalaemia
161718192021222324

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
CTY
City Of London Investment
LSE
0.18%
HHV
Hargreave
LSE
0.00%
CASP
Caspian Sunrise
LSE
0.00%
PHC
PHC.L
LSE
0.00%
APAX
Apax Global Alpha
LSE
0.00%
Trending
ITM
Itm Power
LSE
-10.85%
GST
GSTechnologies
LSE
8.11%
PPP
Pennpetro Energy
LSE
0.00%
EZJ
easyJet
LSE
0.34%
NANO
Nanoco
LSE
-10.69%